65 reports

  • Risk Factors for Pancreatic Cancer
  • presents the risk factors for pancreatic cancer.

Table ##: Risk Factors for Pancreatic Cancer Risk Factors Description Source Smoking The risk of pancreatic cancer increases with age.

  • Pancreatic Cancer
  • Japan
  • United States
  • World
  • Forecast
  • Imbruvica's Development in Pancreatic Cancer
  • Napabucasin's Development in Pancreatic Cancer

INITIALLY APPROVED IN JAPAN FOR GASTRIC CANCER IN 1999, TS-## WAS SUBSEQUENTLY APPROVED FOR PANCREATIC CANCER IN 2006.

  • Pancreatic Cancer
  • AbbVie Inc.
  • AstraZeneca PLC
  • Halozyme Therapeutics, Inc.
  • Merck & Co., Inc.

Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Pancreatic Cancer
  • France
  • United States
  • World
  • Forecast

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Pancreatic Cancer
  • France
  • Germany
  • United States
  • Market Size

Europe Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Pancreatic Cancer
  • Europe
  • France
  • Germany
  • Forecast

Pancreatic cancer

4385 5000 3900
  • Forecast: Pancreatic Cancer
  • Treatment: Pancreatic Cancer

BIBLIOGRAPHY Pancreatic cancer Disease Coverage | Forecast: Pancreatic Cancer DMKC## US ## ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ##

  • Pancreatic Cancer
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Pancreatic Cancer
  • France
  • Germany
  • Italy
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Japan
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • United States
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • United Kingdom
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Italy
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Germany
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • France
  • Market Size

Pancreatic Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Spain
  • Market Size
  • Staging of Pancreatic Cancer
  • Pancreatic Cancer Tumour Location

Table ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • PANCREATIC CANCER SURVIVAL RATE
  • PROGNOS PANCREATIC CANCER DIAGNOSIS TEST RESULT VARIANCE

Prognos has been performing an extensive investigation into pancreatic cancer.

  • Artificial Intelligence
  • Hospital
  • Pancreatic Cancer
  • United States
  • GE Healthcare Limited

Drug Analysis: Masitinib Product Profiles masitinib : Prostate cancer masitinib : Colorectal cancer (CRC) masitinib : Asthma masitinib : Pancreatic cancer LIST OF FIGURES Figure ##: Masitinib for prostate cancer – SWOT analysis Figure ##: Datamoni

  • Colorectal Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • European Union
  • United States

Drug Overview: Masitinib TABLE OF CONTENTS ## Product Profiles## masitinib : Prostate cancer ## masitinib : Colorectal cancer (CRC) ## masitinib : Asthma ## masitinib : Pancreatic cancer LIST OF FIGURES ## Figure ##: Masitinib for prostate cancer

  • Colorectal Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • European Union
  • United States

FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer ## Feb ##, 2018: MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-## Radioimmunotherapy Phase ## Trial for the Treatment of Pancreatic, Co

  • Cancer
  • Clinical Trial
  • Drug Development
  • Pancreatic Cancer
  • World

According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U. S.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Forecast
  • Market Size

Similarly, the Universities portfolio in Phase II, Phase I, Phase ##, IND/ CTA Filed, Preclinical and Discovery stages comprises ##, ##, ##, ##, ## and ## molecules, respectively.

  • Pancreatic Cancer
  • Therapy

Metastatic Pancreatic Cancer Ongoing Global Clinical Trials Analysis and Outlook ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Key Findings, 2018 ##. ## Snapshot ##. ## Overview of Metastatic Pancreatic Cancer Trials ## Clinical Trials Trends to ##

  • Cancer
  • Clinical Trial
  • Drug Development
  • Pancreatic Cancer
  • Pathology
  • Metastatic Pancreatic Cancer Overview
  • Metastatic Pancreatic Cancer - Dormant Projects

EndoTAG-## has been designated orphan drug status in Europe and the US for the treatment of pancreatic cancer.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative

Pancreatic Cancer Pipeline Highlights – 2017 ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • United States
  • Product Initiative
  • Metastatic Pancreatic Cancer Overview
  • Metastatic Pancreatic Cancer - Dormant Projects

Pancreatic cancer that spreads to other organs is called metastatic pancreatic cancer.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative
  • Awareness Projects for Pancreatic Cancer
  • Funding for Research in Pancreatic Cancer

Pancreatic cancer is often referred to as one of the most deadly form of cancer and is known to be a " silent cancer".

  • Pancreatic Cancer
  • World
  • Forecast
  • Market Size
  • PharmaCyte Biotech, Inc.
  • NANOKNIFE SYSTEM - PANCREATIC CANCER
  • NANOKNIFE SYSTEM - PANCREATIC CANCER - PRODUCT DESCRIPTION

## Prostate Cancer ## Renal Failure ## Soft Tissue Injury ## Cancer ## Coronary Artery Disease ## Deep Vein Thrombosis ## Hepatocellular Carcinoma ## Liver Cancer ## Pancreatic Cancer

  • Cell Therapy
  • Drug Delivery
  • Pancreatic Cancer
  • Transdermal Delivery
  • AngioDynamics, Inc.
  • Small Molecules to Inhibit Pim Kinase for Pancreatic Cancer - Drug Profile
  • Products under Development by Companies, H2 2018

The drug candidate is in preclinical stage of development for solid tumors including breast cancer, colon cancer, liver cancer, lung cancer, pancreatic cancer, acute myelocytic leukemia, relapsed and refractory multiple myeloma.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • JUL 10, 2017: HEMISPHERX UPDATES STATUS OF IMMUNO-ONCOLOGY PROGRAM IN PANCREATIC CANCER
  • FEB 26, 2018: HEMISPHERX TO SUPPLY AMPLIGEN FOR PANCREATIC CANCER PATIENTS IN CANADA UNDER SPECIAL ACCESS PROGRAM

Pancreatic cancer is an extremely lethal malignancy with a ##% mortality rate.

  • Pancreatic Cancer
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • OPTUNE - PANCREATIC CANCER
  • OPTUNE - PANCREATIC CANCER - PRODUCT DESCRIPTION

## Hepatocellular Carcinoma ## Lung Cancer ## Malignant Melanoma ## Mesothelioma ## Ovarian Cancer ## Pancreatic Cancer ## Prostate Cancer ## Renal Adenocarcinoma ## Small Cell Lung

  • Pancreatic Cancer
  • Therapy
  • United States
  • Company
  • Novocure